Up to 40% of IBD patients may experience EIMs, with higher risks in Crohn disease and specific disease locations. Five key risk factors for EIMs include disease type, sex, ocular manifestations, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...

Crohn's disease is a chronic inflammatory disease of the digestive system. Both Crohn's disease and ulcerative colitis are referred to as inflammatory bowel disease (IBD), not to be mistaken for ...

Identification of differences in Crohn's disease between male and female patients could provide useful insights into the etiology, pathophysiology and genetics of the disease. Gupta and colleagues, ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...